Hikma Pharmaceuticals Hits Day Low of GBP 15.22 Amid Price Pressure

Hikma Pharmaceuticals Plc has experienced significant volatility today, with the stock hitting an intraday low of GBP 15.22, reflecting a decline of 13.67% on November 6, 2025. This performance starkly contrasts with the FTSE 100, which has seen a modest gain of 0.64% on the same day.
Over the past week, Hikma's stock has dropped 16.51%, and its one-month performance shows a decrease of 17.51%. Year-to-date, the stock has declined by 23.63%, while the FTSE 100 has gained 19.63%. In the last year, Hikma has underperformed the market significantly, with a return of -16.37% compared to the FTSE 100's 19.64%.

Despite these challenges, Hikma maintains a high management efficiency, evidenced by a return on capital employed (ROCE) of 18.66%. The company also has a relatively low debt-to-equity ratio of 0.50. However, it faces pressures from rising raw material costs, which have increased by 15.37% year-over-year, and a notable decline in pre-tax profit by 31.38% in the latest quarter.